Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
GSK plc GSK
$36.52
+$0.24 (0.66%)
На 17:51, 12 мая 2023
+50.60%
Потенциал через год
Ранг: 1
Ключевые показатели
-
Marketcap
73847700000.00000000
-
week52high
45.14
-
week52low
28.47
-
Revenue
29324000000
-
P/E TTM
13
-
Beta
0.28129700
-
EPS
2.77000000
-
Last Dividend
1.48000000
-
Next Earnings Date
01 февр 2017 г. в 15:59
Описание компании
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| DZ Bank | Hold | Buy | 11 февр 2022 г. |
| Barclays | Equal-Weight | Underweight | 05 ноя 2021 г. |
| SVB Leerink | Market Perform | Outperform | 23 мар 2021 г. |
| Deutsche Bank | Sell | Hold | 04 февр 2021 г. |
| Deutsche Bank | Hold | 15 янв 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Is Biotech Immunocore About To Make A 25% Price Move?
MarketBeat
07 февр 2023 г. в 07:00
The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.
GSK's Innovative Specialty Products Need More Insurance Coverage, Still A Buy
Seeking Alpha
03 февр 2023 г. в 01:33
Rukobia is a bright spot, but it's a pill, thus enjoying almost universal coverage. Kaiser Permanente recognizes their worth.
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
Zacks Investment Research
02 февр 2023 г. в 18:04
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
GSK: Top investment bank has its say after drug giant's better-than-expected results
Proactive Investors
02 февр 2023 г. в 06:49
The current year looks to be ‘shaping up nicely' for GSK PLC (LSE:GSK, NYSE:GSK), according to Barclays Capital in the wake of Wednesday's fourth-quarter and full-year results. It did, however, say it is trimming down forecast sales for HIV products going forward to incorporate 'stocking impacts'.
GSK chronic kidney disease drug receives green light
Proactive Investors
02 февр 2023 г. в 05:58
The US Food and Drug Administration (FDA) has given the green light to Jesduvroq, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of adults with chronic kidney disease (CKD) and anaemia who are on dialysis for at least four months. Developed by GSK PLC (LSE:GSK, NYSE:GSK), Jesduvroq is the first innovative medicine for anaemia treatment in over 30 years and the only HIF-PHI approved in the US.